Lei Qi

Prof. Dr. Lei Qi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
GYGaoya Yu
Gaoya Yu
YCYongqin Chen
Yongqin Chen
KLKe Li
Ke Li
LQLei Qi
Lei Qi
LWLiang Wang
Liang Wang
Sarcopenia is a progressive age-related condition characterized by the decline of skeletal muscle mass and function. Its development involves multiple cell

30 June 2025 in Neurospine
Verified
Journal Article
Open access
PDF file
LCLingxiao Chen
Lingxiao Chen
JDJiaming Ding
Jiaming Ding
ZCZhuo Chen
Zhuo Chen
DADavid B Anderson
David B Anderson
MRMaja R. Radojčić
Maja R. Radojčić
SFShiqing Feng
Shiqing Feng
Objective: This study aimed to determine the rates, causes, and predictive factors of readmissions at different periods following spine surgery, up to 180 days.Methods: This study utilized data from the 2018 to 2019 Nationwide Readmissions Database and included four postoperative periods: 0 to 7 days, 8 to 30 days, 31 to 90 days, and 91 to 180 days. The causes of readmissions and potential predictive factors were systematically identified. All analyses were performed for each period.Results: For the 180,281 patients (mean age, 65.4 years) included, 2.4% were readmitted between 0 and 7 days, 3.5% between 8 and 30 days, 3.7% between 31 and 90 days, and 4.3% between 91 and 180 days (cumulative rates: 2.4%, 5.9%, 9.3%, and 12.1%, respectively). The causes of readmissions varied across different periods: surgical site-related causes predominated within the first 30 days, whereas nonsurgical site-related causes were more prevalent from 31 to 180 days; other surgical care complication (e.g., infection) was the most prevalent cause between 0 and 7 days (10.7%) and between 8 and 30 days (29.2%), while spondylopathies/spondyloarthropathy (e.g., spinal stenosis) were the leading causes between 31 and 90 days (12.6%) and between 91 and 180 days (17.5%). The predictive factors associated with readmissions also varied across different periods. For example, patients who underwent fusion was associated with a decreased risk of readmissions between 31 and 180 days (e.g., between 91 and 180 days: odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72–0.86; p<0.001), rather than between 0 and 30 days (e.g., between 0 and 7 days: OR, 0.99; 95% CI, 0.90–1.08; p=0.81).Conclusion: About 6% of patients with lumbar spinal stenosis who underwent spine surgery were readmitted within 30 days and 12% by 180 days. The causes of readmissions and predictive factors varied by period, providing valuable insights for quality improvement efforts and the burden of readmission reductions.

3 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YLYongfu Lou
Yongfu Lou
DMDaoyi Ma
Daoyi Ma
QGQingquan Gan
Qingquan Gan
XXXianyue Xu
Xianyue Xu
YXYiming Xiao
Yiming Xiao
SFShiqing Feng
Shiqing Feng
Background: Degenerative lumbar spine disorders (DLSD), including intervertebral disc disorders (IDD), degenerative spondylolisthesis, and lumbar spinal stenosis (LSS), are major contributors to low back pain and disability. Associations among gut microbiota (GM), inflammatory proteins, and DLSD have been demonstrated in prior studies. Yet, two key questions persist: whether specific circulating inflammatory proteins (IPs) mediate this association, and whether such mediation is shared across different diseases. Methods: We performed two-sample Mendelian randomization (MR) to evaluate causal associations among 473 GM taxa, 91 circulating IPs, and three DLSD outcomes using FinnGen R12 summary statistics. Causal estimates were obtained using inverse-variance weighted MR with complementary sensitivity analyses, pleiotropy and heterogeneity testing, and bidirectional MR. Two-step MR mediation was applied to quantify indirect effects of GM through IPs. Experimental validation was performed using rat models, with qPCR and ELISA assessing inflammatory markers in lumbar tissues and metagenomic sequencing evaluating gut microbiota profiles. Results: Genetically predicted GM taxa were associated with LSS (28 taxa), spondylolisthesis (20 taxa), and IDD (41 taxa). IP MR identified risk-increasing associations for LSS (4E-BP1 and interleukin-4), spondylolisthesis (CXCL1, CXCL5, FGF-5, IL-15RA, and IL-4) and IDD (IL-20RA and IL-6), while IL-18 showed a protective association with IDD that remained robust after multiple-testing correction. Mediation analyses identified 13 genetically supported putative GM–IPs–DLSD pathways, highlighting convergent mediators including PD-L1 for spondylolisthesis and IL-6 and IL-18 for IDD, with mediation proportions ranging from 7.55% to 13.22% across key pathways. Experimental results showed inflammatory activation and gut microbiota alterations in disease models, with partial concordance with the MR findings. Conclusions: These findings support a genetically determined microbiota–inflammation axis in DLSD. Furthermore, they identify circulating inflammatory proteins as mediators to prioritize mechanistic studies and guide translational follow-up research.

12 May 2026 in Toxicology
Verified
Journal Article
Closed access
ZWZhenyang Wang
Zhenyang Wang
YCYongqin Chen
Yongqin Chen
JMJiling Ma
Jiling Ma
YYYuxuan Yang
Yuxuan Yang
KLKe Li
Ke Li
LQLei Qi
Lei Qi

14 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
ZWZhenyang Wang
Zhenyang Wang
YCYongqin Chen
Yongqin Chen
YYYuxuan Yang
Yuxuan Yang
BXBiteng Xu
Biteng Xu
XJXiejia Jiao
Xiejia Jiao
LQLei Qi
Lei Qi
Background: This study investigates the role of N6-methyladenosine (m6A) regulators in osteoporosis (OP) and their interplay with the immune microenvironment, aiming to identify potential m6A-related biomarkers for OP risk assessment and treatment. Methods: Transcriptomic data from GEO datasets were analyzed for differential expression of 22 m6A regulators and immune infiltration patterns. Consensus clustering and m6Ascore grouping defined molecular subtypes, while machine learning algorithms identified potential biomarkers, leading to the construction and validation of a nomogram. Experimental validation involved peripheral blood monocytes (PBMCs) transcriptome sequencing and Western blot of bone tissue. Results: FTO, HNRNPC, and METTL4 were upregulated, while CBLL1 and YTHDF2 were downregulated in OP, with two distinct m6A modification patterns and immune phenotypes identified. METTL4, HIRA, MATN4, and YTHDF2 were selected as potential biomarkers, and the nomogram demonstrated favorable predictive performance in training and external datasets. Single-cell RNA sequencing confirmed the cellular distribution of these biomarkers. HIRA heterogeneity in Marrow Mesenchymal Stem Cells (BMSCs) was associated with distinct cell–cell communication patterns. Transcriptome sequencing confirmed HIRA RNA downregulation in OP PBMCs, and Western blot verified decreased HIRA protein in OP bone tissue. Conclusions: This study establishes a potential m6A-related biomarker signature for OP and provides multi-level experimental evidence that HIRA is a consistently downregulated biomarker, linking epigenetic modification to immune dysregulation in osteoporosis.

19 May 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
YCYongqin Chen
Yongqin Chen
XJXiejia Jiao
Xiejia Jiao
BXBiteng Xu
Biteng Xu
YYYuxuan Yang
Yuxuan Yang
XXXiao Xu
Xiao Xu
LQLei Qi
Lei Qi